Table 3.
Analysis of liver therapy efficacy
| Result | Experimental group (%) | Control group (%) | Total | Statistics | P |
|---|---|---|---|---|---|
| No liver function abnormalities or symptoms | 173 (62.45) | 193 (66.32) | 366 | ||
| Transient liver function abnormalities or symptoms | 95 (34.30) | 80 (27.49) | 175 | -0.649 | 0.516 |
| Liver injury and symptoms with interrupted anti-TB treatment | 9 (3.25) | 18 (6.19) | 27 | ||
| Total | 277 | 291 | 568 |
Note: The groups were compared using the Wilcoxon test.